Targeted Technology

Targeted Technology, established in 2009 and headquartered in San Antonio, Texas, is a venture capital firm specializing in early-stage investments. It focuses on technology-driven life science and healthcare companies, with a particular interest in medical devices, biotechnology, diagnostics, and specialty pharmaceuticals. The firm invests in companies across the United States, with a preference for those based in the South Eastern and South Western regions, including Texas, Alabama, and Georgia. Targeted Technology seeks to back innovative startups that can advance disruptive technologies, improve patient outcomes, and enhance the efficiency of life science product development and manufacturing.

Paul Castella

Senior Managing Partner

Ian Clements

Managing Partner

Alan Dean

Co-Founder and Senior Managing Partner

Corey Levenson

Associate Partner

Jim Traa

Managing Partner

13 past transactions

Cardiovate

Seed Round in 2017
Cardiovate, Inc. is a medical technology company based in San Antonio, Texas, founded in 2012. The company specializes in developing innovative tissue regeneration and repair products, with a focus on addressing critical needs in healthcare. Its flagship product, NeoVessel, is a vascular graft designed to facilitate the regeneration and repair of vascular tissues. By employing proprietary materials and advanced processes, Cardiovate aims to enhance the efficacy of medical devices in this field, ultimately reducing failure rates and lowering the overall cost of care.

neoSurgical

Series B in 2017
neoSurgical Limited is an Irish company focused on developing innovative medical devices specifically for laparoscopic abdominal surgery. Established in 2007 and located in Campus, Ireland, neoSurgical has created the neoClose technology, which is designed to assist surgeons by enhancing the safety and efficiency of closing laparoscopic incision sites. This product aims to reduce the risk of herniation complications associated with laparoscopic procedures, thereby improving patient outcomes. Through its commitment to technical innovation, neoSurgical seeks to address challenges within the surgical devices industry.

Aerin Medical

Series C in 2016
Aerin Medical is a health technology company that develops non-invasive therapeutic devices to improve nasal breathing. Its portfolio includes VivAer for nasal airway obstruction and RhinAer for chronic rhinitis, along with VivAer Stylus and RhinAer Stylus, plus a compact console that delivers temperature-controlled radiofrequency energy to remodel nasal soft tissue. The technology targets the underlying causes of nasal congestion and offers alternatives to invasive surgery. The company, founded in 2011, is based in Sunnyvale, California.

Roxy’s Remedies

Series A in 2016
Roxy’s Remedies provides natural grooming products for dogs with canine atopic dermatitis. Roxy’s Remedies' product line is formulated with sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO) produced by TFS Corporation Ltd. EISO is a natural, calming ingredient that has been used as a traditional skin healing agent and is being developed by Santalis as a prescription drug for human skin conditions.

StemBioSys

Series A in 2015
Founded in 2010, StemBioSys specializes in the isolation, expansion, and delivery of adult stem cells for research, diagnostic, and clinical purposes. The company's flagship product, BM-HPME, is an advanced stem cell culture system that mimics the natural three-dimensional environment for optimal stem cell growth.

Xenex

Venture Round in 2015
Xenex is a company dedicated to reducing healthcare-associated infections (HAIs) through its innovative disinfection technology. Founded in 2009 and headquartered in San Antonio, Texas, Xenex develops a portable ultraviolet room disinfection system that employs pulsed xenon UV light to effectively eliminate harmful microorganisms, including bacteria and viruses, in healthcare environments. Since its commercial introduction in 2010, Xenex's devices have been integrated into infection control protocols in nearly three hundred hospitals across the United States. The company's mission focuses on saving lives and alleviating suffering by significantly lowering the bacterial load that contributes to the risk of HAIs, thereby protecting patients, healthcare staff, and the financial health of medical facilities.

DNAtrix

Series B in 2014
DNAtrix, Inc. is a clinical-stage biotechnology company based in Houston, Texas, with an additional office in San Diego, California. The company specializes in developing virus-driven immunotherapies for cancer treatment, focusing initially on glioblastoma, a highly aggressive and currently untreatable brain tumor. Its lead product, DNX-2401, is a modified oncolytic virus derived from a common cold virus, designed to selectively target and kill cancer cells. This innovative approach has shown promising results, with over 35 patients treated and positive early outcomes reported. In addition to DNX-2401, DNAtrix is advancing other candidates such as DNX-2440 and DNX-2450 for solid tumors, as well as MYX-135 for hematological malignancies. The company also has a strategic partnership with Valo Therapeutics, further enhancing its research and development capabilities in the field of cancer immunotherapy.

Bluegrass Vascular Technologies

Series A in 2014
Bluegrass Vascular Technologies, Inc. is a medical technology company based in San Antonio, Texas, founded in 2010. The company specializes in developing and commercializing innovative devices aimed at improving vascular access procedures for patients with obstructed central venous systems. Its flagship product, the Surfacer Inside-Out Access Catheter System, allows physicians to achieve central venous access by utilizing a guide wire that is inserted through the femoral vein and navigated to exit at the jugular or subclavian vein. This system is designed to enhance patient safety and reduce complications during venous access procedures, and it has been successfully used in over 400 procedures for patients with venous occlusive disease. Bluegrass Vascular Technologies operates both in the United States and internationally.

Xenex

Venture Round in 2013
Xenex is a company dedicated to reducing healthcare-associated infections (HAIs) through its innovative disinfection technology. Founded in 2009 and headquartered in San Antonio, Texas, Xenex develops a portable ultraviolet room disinfection system that employs pulsed xenon UV light to effectively eliminate harmful microorganisms, including bacteria and viruses, in healthcare environments. Since its commercial introduction in 2010, Xenex's devices have been integrated into infection control protocols in nearly three hundred hospitals across the United States. The company's mission focuses on saving lives and alleviating suffering by significantly lowering the bacterial load that contributes to the risk of HAIs, thereby protecting patients, healthcare staff, and the financial health of medical facilities.

ViroXis

Private Equity Round in 2013
ViroXis Corporation is a bio-pharmaceutical company based in San Antonio, Texas, that specializes in the development and commercialization of innovative botanical pharmaceuticals derived from East Indian sandalwood oil. Founded in 2006, the company has created a botanical ointment formulated from Santalum album oil, which is used to treat human papillomavirus (HPV) infections of the skin in both children and adults. Additionally, ViroXis is developing an EISO cream aimed at addressing other HPV infections and skin pox. The company has established strategic partnerships with TFS Corporation Ltd. and DPT Laboratories, Inc., enhancing its capabilities in the biopharmaceutical sector.

Bi02 Medical

Series C in 2012
Bi02 Medical, Inc. is a medical device company that specializes in designing, developing, manufacturing, and commercializing innovative solutions for clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter aimed at preventing pulmonary embolism and enabling access to the central venous system in critically ill patients. This catheter-based device allows for the administration of medications, fluids, or blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical operates through a network of distribution partners globally. Founded in 2006, the company is headquartered in San Antonio, Texas, and maintains a research and development and manufacturing facility in Golden, Colorado.

Bi02 Medical

Series B in 2012
Bi02 Medical, Inc. is a medical device company that specializes in designing, developing, manufacturing, and commercializing innovative solutions for clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter aimed at preventing pulmonary embolism and enabling access to the central venous system in critically ill patients. This catheter-based device allows for the administration of medications, fluids, or blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical operates through a network of distribution partners globally. Founded in 2006, the company is headquartered in San Antonio, Texas, and maintains a research and development and manufacturing facility in Golden, Colorado.

VidaCare

Venture Round in 2009
Vidacare Corporation is a medical device company based in San Antonio, Texas, specializing in intraosseous access technology. Founded in 2001, the company develops, manufactures, and markets devices designed for diagnostic, monitoring, and therapeutic applications, particularly in emergency situations where traditional vascular access is challenging. Its primary product, the EZ-IO Product System, enables controlled vascular access through the intraosseous route, utilizing a power driver that drills through bone to secure placement. Additionally, Vidacare offers a suite of products for hematology and oncology, including tools for bone marrow aspiration and biopsy. Its offerings are utilized in various settings, including pre-hospital care, emergency response, and military applications, addressing critical needs in bone and blood-related medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.